http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 06:54:43 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Gilead+Sciences+%28GILD%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+post+CFO+Chat/26656628.html <p>Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $155.00 price target on Gilead Sciences (NASDAQ: GILD).</p><p>The analyst commented, "We hosted the Gilead CFO and Head of IR Tuesday evening to catch up on the business, all things Yeztugo and broader HIV, as well as some less appreciated parts of the pipeline. Easily the parts that stood out included (1) PrEP portfolio messaging following last night’s news (see our take: “Once Weekly, Twice the Optionality for Yeztugo”, 6/15/2026; link), (2) Trodelvy TNBC messaging that emphasized a positive commercial outlook ($3-4bn peak sales potential) driven by 1L adoption, longer duration, http://www.streetinsider.com/Analyst+Comments/Gilead+Sciences+%28GILD%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+post+CFO+Chat/26656628.html Wed, 17 Jun 2026 06:54:43 -0400 GILD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jun+15++Filed+by%3A+Mercier+Johanna/26655504.html si-local-file:///var/storage/secattach/20260616/26655504.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jun+15++Filed+by%3A+Mercier+Johanna/26655504.html Tue, 16 Jun 2026 18:02:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jun+15++Filed+by%3A+Mercier+Johanna/26655504.html si-local-file:///var/storage/secattach/20260616/26655504.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jun+15++Filed+by%3A+Mercier+Johanna/26655504.html Tue, 16 Jun 2026 18:02:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jun+15++Filed+by%3A+Dickinson+Andrew+D/26655469.html si-local-file:///var/storage/secattach/20260616/26655469.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jun+15++Filed+by%3A+Dickinson+Andrew+D/26655469.html Tue, 16 Jun 2026 17:53:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jun+15++Filed+by%3A+Dickinson+Andrew+D/26655469.html si-local-file:///var/storage/secattach/20260616/26655469.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jun+15++Filed+by%3A+Dickinson+Andrew+D/26655469.html Tue, 16 Jun 2026 17:53:00 -0400 GILD O.00092067 http://www.streetinsider.com/Analyst+Comments/Gilead+Sciences+%28GILD%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+on+FDA+Approval+/26650323.html <p>Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $155.00 price target on Gilead Sciences (NASDAQ: GILD).</p><p>The analyst commented, "Gilead announced FDA acceptance of 300 mg QW oral Yeztugo for HIV PrEP (Feb 2, 2027 PDUFA). Given that the Street wasn’t even aware of a filing, this will likely be met with surprise by much of the Street, and sets up for it to the first longer-acting oral (LAO) regimen in the PrEP setting. We view this as an incremental positive, adding flexibility for patients while strengthening the PrEP franchise against other emerging oral competitors. Indeed, the most notable http://www.streetinsider.com/Analyst+Comments/Gilead+Sciences+%28GILD%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+on+FDA+Approval+/26650323.html Tue, 16 Jun 2026 07:05:28 -0400 GILD http://www.streetinsider.com/Corporate+News/Gilead+Sciences%3A+FDA+accepts+GILEAD+application+for+once-weekly+oral+HIV+prevention+pill/26647943.html <p>Gilead Sciences (NASDAQ: GILD) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for Yeztugo (lenacapavir) as a once-weekly oral tablet for HIV pre-exposure prophylaxis (PrEP). The FDA has set a PDUFA action date of February 2, 2027.</p><p>The application covers a 300-mg oral tablet taken once weekly. If approved, Gilead claims the formulation would be the first long-acting oral PrEP option. The drug is currently not approved in any oral once-weekly form anywhere globally.</p><p>The submission is supported by data from the PURPOSE 1 and PURPOSE 2 clinical trials, which evaluated lenacapavir for PrEP across http://www.streetinsider.com/Corporate+News/Gilead+Sciences%3A+FDA+accepts+GILEAD+application+for+once-weekly+oral+HIV+prevention+pill/26647943.html Mon, 15 Jun 2026 16:34:40 -0400 GILD http://www.streetinsider.com/FDA/Gilead+Sciences%3A+FDA+accepts+GILEAD+application+for+once-weekly+oral+HIV+prevention+pill/26647943.html <p>Gilead Sciences (NASDAQ: GILD) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for Yeztugo (lenacapavir) as a once-weekly oral tablet for HIV pre-exposure prophylaxis (PrEP). The FDA has set a PDUFA action date of February 2, 2027.</p><p>The application covers a 300-mg oral tablet taken once weekly. If approved, Gilead claims the formulation would be the first long-acting oral PrEP option. The drug is currently not approved in any oral once-weekly form anywhere globally.</p><p>The submission is supported by data from the PURPOSE 1 and PURPOSE 2 clinical trials, which evaluated lenacapavir for PrEP across http://www.streetinsider.com/FDA/Gilead+Sciences%3A+FDA+accepts+GILEAD+application+for+once-weekly+oral+HIV+prevention+pill/26647943.html Mon, 15 Jun 2026 16:34:40 -0400 GILD http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html <p class="bwalignc"> <b><i>– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo<b>®</b> (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. </p><p> “This filing reflects Gilead’s continued commitment to advancing new HIV prevention options,” said Dietmar Berger, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html Mon, 15 Jun 2026 16:34:00 -0400 A.06822034 GILD O.00092067 O.20026344 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html <p class="bwalignc"> <b><i>– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo<b>®</b> (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. </p><p> “This filing reflects Gilead’s continued commitment to advancing new HIV prevention options,” said Dietmar Berger, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html Mon, 15 Jun 2026 16:34:00 -0400 A.06822034 GILD O.00092067 O.20026344 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html <p class="bwalignc"> <b><i>– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo<b>®</b> (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. </p><p> “This filing reflects Gilead’s continued commitment to advancing new HIV prevention options,” said Dietmar Berger, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html Mon, 15 Jun 2026 16:34:00 -0400 A.06822034 GILD O.00092067 O.20026344 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html <p class="bwalignc"> <b><i>– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo<b>®</b> (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. </p><p> “This filing reflects Gilead’s continued commitment to advancing new HIV prevention options,” said Dietmar Berger, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html Mon, 15 Jun 2026 16:34:00 -0400 A.06822034 GILD O.00092067 O.20026344 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html <p class="bwalignc"> <b><i>– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo<b>®</b> (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. </p><p> “This filing reflects Gilead’s continued commitment to advancing new HIV prevention options,” said Dietmar Berger, http://www.streetinsider.com/Business+Wire/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html Mon, 15 Jun 2026 16:34:00 -0400 A.06822034 GILD O.00092067 O.20026344 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html <p class="bwalignc"> <b><i>– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo<b>®</b> (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. </p><p> “This filing reflects Gilead’s continued commitment to advancing new HIV prevention options,” said Dietmar Berger, http://www.streetinsider.com/Business+Wire/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html Mon, 15 Jun 2026 16:34:00 -0400 A.06822034 GILD O.00092067 O.20026344 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html <p class="bwalignc"> <b><i>– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo<b>®</b> (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. </p><p> “This filing reflects Gilead’s continued commitment to advancing new HIV prevention options,” said Dietmar Berger, http://www.streetinsider.com/Business+Wire/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html Mon, 15 Jun 2026 16:34:00 -0400 A.06822034 GILD O.00092067 O.20026344 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html <p class="bwalignc"> <b><i>– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo<b>®</b> (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. </p><p> “This filing reflects Gilead’s continued commitment to advancing new HIV prevention options,” said Dietmar Berger, http://www.streetinsider.com/Business+Wire/U.S.+FDA+Accepts+Gilead%E2%80%99s+Application+for+Investigational+Once-Weekly+Oral+Yeztugo%2C+Potentially+the+First+Long-Acting+Pill+for+HIV+Prevention/26647930.html Mon, 15 Jun 2026 16:34:00 -0400 A.06822034 GILD O.00092067 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Dickinson+Andrew+D/26647872.html si-local-file:///var/storage/secattach/20260615/26647872.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Dickinson+Andrew+D/26647872.html Mon, 15 Jun 2026 16:31:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Dickinson+Andrew+D/26647872.html si-local-file:///var/storage/secattach/20260615/26647872.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Dickinson+Andrew+D/26647872.html Mon, 15 Jun 2026 16:31:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Mercier+Johanna/26647394.html si-local-file:///var/storage/secattach/20260615/26647394.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Mercier+Johanna/26647394.html Mon, 15 Jun 2026 16:09:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Mercier+Johanna/26647394.html si-local-file:///var/storage/secattach/20260615/26647394.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Mercier+Johanna/26647394.html Mon, 15 Jun 2026 16:09:00 -0400 GILD O.00092067 http://www.streetinsider.com/Corporate+News/Gilead+donates+remdesivir+to+Uganda+for+Ebola+outbreak+response/26638547.html <p>Gilead Sciences (NASDAQ: GILD) announced a donation of more than 2,000 vials of remdesivir to Uganda to support the country's response to the current Ebola Bundibugyo virus disease outbreak.</p><p>The intravenous antiviral therapy is being provided under compassionate use and Monitored Emergency Use of Unregistered and Investigational Interventions frameworks. Gilead is preparing additional supply and readying support for requests from the Democratic Republic of the Congo, the World Health Organization and other regional partners.</p><p>The company plans to provide both remdesivir and obeldesivir, an oral investigational antiviral agent, as part of the broader regional response to Ebola BVD, including support for planned http://www.streetinsider.com/Corporate+News/Gilead+donates+remdesivir+to+Uganda+for+Ebola+outbreak+response/26638547.html Fri, 12 Jun 2026 08:30:53 -0400 GILD http://www.streetinsider.com/FDA/Gilead+donates+remdesivir+to+Uganda+for+Ebola+outbreak+response/26638547.html <p>Gilead Sciences (NASDAQ: GILD) announced a donation of more than 2,000 vials of remdesivir to Uganda to support the country's response to the current Ebola Bundibugyo virus disease outbreak.</p><p>The intravenous antiviral therapy is being provided under compassionate use and Monitored Emergency Use of Unregistered and Investigational Interventions frameworks. Gilead is preparing additional supply and readying support for requests from the Democratic Republic of the Congo, the World Health Organization and other regional partners.</p><p>The company plans to provide both remdesivir and obeldesivir, an oral investigational antiviral agent, as part of the broader regional response to Ebola BVD, including support for planned http://www.streetinsider.com/FDA/Gilead+donates+remdesivir+to+Uganda+for+Ebola+outbreak+response/26638547.html Fri, 12 Jun 2026 08:30:53 -0400 GILD http://www.streetinsider.com/Press+Releases/Gilead+Mobilizes+Rapid+Donation+of+Remdesivir+to+Support+Ebola+Response%2C+Building+on+Decade-Long+Commitment+to+Outbreak+Relief/26638533.html <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company’s long-standing work to address emerging infectious diseases.</p><p>“At Gilead, we recognize the urgency and human toll of global health emergencies – and the responsibility to act quickly,” said Anu Osinusi, MD, Vice President, Clinical Development, Virology at Gilead Sciences. “Building on decades of experience responding http://www.streetinsider.com/Press+Releases/Gilead+Mobilizes+Rapid+Donation+of+Remdesivir+to+Support+Ebola+Response%2C+Building+on+Decade-Long+Commitment+to+Outbreak+Relief/26638533.html Fri, 12 Jun 2026 08:30:00 -0400 A.17568957 GILD O.00092067 O.04889877 http://www.streetinsider.com/Press+Releases/Gilead+Mobilizes+Rapid+Donation+of+Remdesivir+to+Support+Ebola+Response%2C+Building+on+Decade-Long+Commitment+to+Outbreak+Relief/26638533.html <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company’s long-standing work to address emerging infectious diseases.</p><p>“At Gilead, we recognize the urgency and human toll of global health emergencies – and the responsibility to act quickly,” said Anu Osinusi, MD, Vice President, Clinical Development, Virology at Gilead Sciences. “Building on decades of experience responding http://www.streetinsider.com/Press+Releases/Gilead+Mobilizes+Rapid+Donation+of+Remdesivir+to+Support+Ebola+Response%2C+Building+on+Decade-Long+Commitment+to+Outbreak+Relief/26638533.html Fri, 12 Jun 2026 08:30:00 -0400 A.17568957 GILD O.00092067 O.04889877 http://www.streetinsider.com/Press+Releases/Gilead+Mobilizes+Rapid+Donation+of+Remdesivir+to+Support+Ebola+Response%2C+Building+on+Decade-Long+Commitment+to+Outbreak+Relief/26638533.html <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company’s long-standing work to address emerging infectious diseases.</p><p>“At Gilead, we recognize the urgency and human toll of global health emergencies – and the responsibility to act quickly,” said Anu Osinusi, MD, Vice President, Clinical Development, Virology at Gilead Sciences. “Building on decades of experience responding http://www.streetinsider.com/Press+Releases/Gilead+Mobilizes+Rapid+Donation+of+Remdesivir+to+Support+Ebola+Response%2C+Building+on+Decade-Long+Commitment+to+Outbreak+Relief/26638533.html Fri, 12 Jun 2026 08:30:00 -0400 A.17568957 GILD O.00092067 O.04889877